PLX
AMEXProtalix BioTherapeutics Inc. (DE)
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.99-0.01 (-0.75%)
01:30 PM07:45 PM
News · 26 weeks23-83%
2025-12-142026-06-07
Mix1090d
- SEC Filings6(60%)
- Earnings3(30%)
- Insider1(10%)
Latest news
25 items- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECSEC Form 10-Q filed by Protalix BioTherapeutics Inc. (DE)10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- PRProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business ResultsCompany to host conference call and webcast today at 8:00 a.m. EDTElfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from ChiesiPRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from ChiesiCash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX
- PRProtalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026Company to host conference call and webcast at 8:00 a.m. EDTCARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended March 31, 2026 and provide a business update on May 13, 2026. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.Conference Call Details:Date: Wednesday, May 13, 2026Ti
- SECSEC Form DEF 14A filed by Protalix BioTherapeutics Inc. (DE)DEF 14A - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- INSIDERAmendment: New insider Mamlok Gilad claimed ownership of 3,631 shares (SEC Form 3)3/A - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- SECSEC Form 10-K filed by Protalix BioTherapeutics Inc. (DE)10-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- PRProtalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsCompany to host conference call and webcast today at 8:00 a.m. EDTThe European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in adults living with Fabry disease providing a meaningful reduction in treatment burden without compromising efficacyThe EC approval triggered the Company's entitlement to a $25.0 million milestone payment from Chiesi, strengthening the Company's cash position and supporting an expected cash balance of approximately $50.0 million by April 2026Based on current estimates, management expects total revenues in 2026 to range from approximately $78.0 million to $83.0 million including the $25.0 million payment referenced aboveThe Phase
- PRProtalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026Company to host conference call and webcast at 8:00 a.m. EDTCARMIEL, Israel, March 11, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the fiscal year ended December 31, 2025 and provide a business update on March 18, 2026. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.Conference Call Details:Date: Wednesday, March 18, 2026Time: 8:00 a.m.
- PRChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those stable with an enzyme replacement therapy (ERT) With this decision, announced ahead of Fabry Disease Awareness Month in April, Chiesi Global Rare Diseases will work with countries across the EU to support broader access to this additional dosing schedule for the adult Fabry community PARMA, Italy and CARMIEL, Israel, March 09, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living wit
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- PRChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the FDA-approved dosing regimen remains 1mg/kg every 2 weeks. Please see Important Safety Information below and the Full Prescribing Information, including Boxed Warning. European Commission approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval frequency from every-two-weeks to every-four-weeks for those stable with an enzyme replacement therapy (ERT) With this decision, announced ahead of Fabry Disease Awareness Mon
- PREllomay Capital Announces Changes in its Principal Shareholders and Board CompositionTel-Aviv, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) ("Ellomay" or the "Company"), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and the USA, today announced that its principal shareholders, S. Nechama Investments (2008) Ltd., Kanir Joint Investments (2005) LP and Ms. Anat Raphael, who together currently hold approximately 45.9% of the Company's outstanding share capital, informed it that they have completed the sale of all of the Company's ordinary shares held by them to O.Y. Nofar Energy Ltd. ("Nofar"), a public company listed on the Tel Aviv Stock Exchange Ltd. (TASE: NOFR).
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- PRChiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EUCommittee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible adult patients, their families and the broader healthcare system due to the current requirement to visit infusion centres or have home infusions every-2-weeks for treatment PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protali
- PRChiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EUCommittee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible patients, their families, and the broader healthcare system due to the current requirement to visit infusion centres every two weeks for treatment This dosing regimen for Elfabrio is not approved in the U.S. In the U.S., the approved dosing regimen remains 1 mg/kg every 2 weeks. Please consult with your healthcare provider PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- PRProtalix BioTherapeutics Letter to StockholdersCARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced the following update from President and Chief Executive Officer, Dror Bashan, to its stockholders. Dear Protalix Stockholders, As we look forward to 2026, we remain focused on building with our partners a growing, profitable business and an innovative pipeline for patients with high-need rare diseases. A core element of this plan is our advancement of PRX-115 for patients with uncontrolled gout. Clinical data from o
- INSIDERPRESIDENT AND CEO Bashan Dror bought $101,360 worth of shares (56,000 units at $1.81), increasing direct ownership by 42% to 188,516 units (SEC Form 4)4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- PRProtalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option AgreementPartnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications Protalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercialization CARMIEL, Israel and MARTINSRIED, Germany, Dec. 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, and Secarna Pharmaceuticals GmbH & Co. KG, a company re
- INSIDERDirector Bar-Shalev Amos sold $314 worth of shares (168 units at $1.87), closing all direct ownership in the company (SEC Form 4)4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- SECSEC Form 10-Q filed by Protalix BioTherapeutics Inc. (DE)10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
PLX FAQ
5 questionsWhat does Protalix BioTherapeutics Inc. (DE) do?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed...Where does PLX stock trade?
Protalix BioTherapeutics Inc. (DE) (PLX) is listed on AMEX.What sector and industry is PLX in?
Protalix BioTherapeutics Inc. (DE) operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to PLX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PLX side-by-side with any of them on Quantisnow.How can I track PLX on Quantisnow?
Quantisnow aggregates Protalix BioTherapeutics Inc. (DE)'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLX to receive live email and push alerts on every new disclosure.